Quote | Mainz Biomed B.V. (NASDAQ:MYNZ)
Last: | $0.3549 |
---|---|
Change Percent: | 2.89% |
Open: | $0.37 |
Close: | $0.3549 |
High: | $0.382 |
Low: | $0.3409 |
Volume: | 774,601 |
Last Trade Date Time: | 07/23/2024 03:00:00 am |
News | Mainz Biomed B.V. (NASDAQ:MYNZ)
--News Direct-- Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer sc...
2024-07-10 08:31:07 ET More on Mainz Biomed B.V. Seeking Alpha’s Quant Rating on Mainz Biomed B.V. Historical earnings data for Mainz Biomed B.V. Financial information for Mainz Biomed B.V. Read the full article on Seeking Alpha For further det...
Message Board Posts | Mainz Biomed B.V. (NASDAQ:MYNZ)
Subject | By | Source | When |
---|---|---|---|
Looks pretty positive | budfoxfun | investorshub | 04/27/2023 10:08:15 PM |
$MYNZ The now | cuggegrosse | investorshub | 04/27/2023 6:07:40 PM |
Thoughts on where this is headed? | Mrogers23 | investorshub | 04/27/2023 5:51:00 PM |
That cat bounced. Poped back over $4. | BooDog | investorshub | 04/27/2023 2:31:33 PM |
$MYNZ The now last up | BlazingStocks | investorshub | 04/27/2023 11:42:39 AM |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer sc...
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sens...
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2024, and provided a cor...